The company's Board has stipulated the following principles, among others, for dealing with any takeover bid:

  • If the Board receives information about a possible or actual takeover bid for the company's shares, the Board shall help ensure that all shareholders are treated equally and receive satisfactory information at all times.
  • In the event of a takeover bid for the company, the Board shall help ensure that the company's activities are run without interruption in relation to normal operations.

  • In the event of a takeover bid, the Board shall not actively hinder the bid unless special reasons indicate that this is in the interests of the shareholders as a whole.

  • The Board shall not attempt to hinder takeover bids by utilising authorisations to issue new shares or reaching other decisions with the aim of hindering the implementation of the bid.

  • If a bid is received, the Board shall publish its assessment of the bid and a recommendation to the shareholders to either accept or reject the bid. The Board shall work to ensure that the shareholders have sufficient time to reach a decision concerning the bid.

The company's Board will continue to work on drawing up guidelines and principles for how the company should handle any takeover bid for the company's shares.

Contact Us

NattoPharma ASA
(head office)
Lilleakerveien 2B
0283 Oslo, Norway
Tel: (+47) 40 00 90 08

NattoPharma USA, Inc.
(North American Subsidiary)
328 Amboy Avenue, Ste. D
Metuchen, NJ 08840, USA
Tel: (+1) 609-454-2992

NattoPharma contact information:
Main office: Lilleakerveien 2B, 0283 Oslo,Norway
North American Subsidary: 328 Amboy Ave.,Ste. D,Metuchen, NJ 08840
Tel: (+47) 40 00 90 08
Tel: (+1) 609-454-2992
Created by:
Nutricon logo.
Search term: